GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (LTS:0JBU) » Definitions » 6-1 Month Momentum %

Intellia Therapeutics (LTS:0JBU) 6-1 Month Momentum % : -32.06% (As of May. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Intellia Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-25), Intellia Therapeutics's 6-1 Month Momentum % is -32.06%.

The industry rank for Intellia Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

LTS:0JBU's 6-1 Month Momentum % is ranked worse than
74.51% of 1526 companies
in the Biotechnology industry
Industry Median: -5.54 vs LTS:0JBU: -32.06

Competitive Comparison of Intellia Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Intellia Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's 6-1 Month Momentum % falls into.



Intellia Therapeutics  (LTS:0JBU) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intellia Therapeutics  (LTS:0JBU) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Intellia Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intellia Therapeutics (LTS:0JBU) Business Description

Traded in Other Exchanges
Address
40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics (LTS:0JBU) Headlines

No Headlines